.Pharmacolibrary.Drugs.ATC.C.C01CE02

Information

Milrinone is a phosphodiesterase 3 inhibitor used mainly for the short-term treatment of acute decompensated heart failure and for patients with severe heart failure unresponsive to conventional therapy. It produces positive inotropic and vasodilatory effects. Milrinone is approved and utilized in hospital settings, particularly in intensive care.

Pharmacokinetics

Pharmacokinetic parameters reported in adult patients with congestive heart failure after intravenous administration.

References

1. Hornik, CP, et al., & Gonzalez, D (2019). Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents. Journal of clinical pharmacology 59(12) 1606–1619. DOI:10.1002/jcph.1499 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31317556

2. Commander, SJ, et al., & Hornik, CP (2022). The relationship between simulated milrinone exposure and hypotension in children. Cardiology in the young 32(5) 782–788. DOI:10.1017/S1047951121003103 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34350821

3. Pellicer, A, et al., & Cabañas, F (2013). Phase 1 study of two inodilators in neonates undergoing cardiovascular surgery. Pediatric research 73(1) 95–103. DOI:10.1038/pr.2012.154 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23138399

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)